Literature DB >> 3610045

Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients.

J Vorobioff, E Picabea, R Villavicencio, V Puccini, O Rossi, J Bordato, M Audano.   

Abstract

Different and contradictory results concerning the use of propranolol in the treatment of portal hypertension have been reported. This study was designed to investigate the hemodynamic effects of short- and long-term administration of propranolol in portal hypertensive patients. Portal pressure, cardiac index, heart rate and blood pressure were obtained in 18 unselected alcoholic cirrhotic patients with esophageal varices before and 60 min after the oral administration of 40 mg propranolol and again after 106 +/- 35 days of continuous oral administration (mean dose = 158 +/- 63 mg per day). Baseline portal pressure was 21.7 +/- 7.2 mm Hg. It decreased after 60 min to 17.2 +/- 5.5 mm Hg (p less than 0.01) and after long-term administration of propranolol to 16.1 +/- 5.7 mm Hg (p less than 0.01). No decrease in portal pressure was noted in 9 of 18 (50%) patients after acute administration and 5 of 17 (30%) patients after long-term administration. Baseline cardiac index was 5.1 +/- 1.2 liters X min-1 X m-2. It decreased after 60 min to 3.9 +/- 1.4 liters X min-1 X m-2 (p less than 0.01) and to 3.6 +/- 1.0 liters X min-1 X m-2 after long-term administration (p less than 0.001). Baseline heart rate was 85 +/- 11 beats per min. It decreased after 60 min to 75 +/- 9 (p less than 0.001) and after long-term administration to 62 +/- 6 (p less than 0.001) beats per min. Baseline mean arterial pressure was 108 +/- 11 Hg. It decreased after 60 min to 97 +/- 14 mm Hg (p less than 0.01) and after long-term administration to 103 +/- 14 mm Hg (not statistically significant).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3610045     DOI: 10.1002/hep.1840070406

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol.

Authors:  S Mies; O B Neto; A Beer; C E Baía; F Alfieri; L M Pereira; M J Sette; S Raia
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

2.  Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: a randomized controlled trial.

Authors:  Binay-K De; Deep Dutta; Rimi Som; Pranab-K Biswas; Subrata-K Pal; Anirban Biswas
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

3.  The effect of propranolol in malay patients with liver cirrhosis - a pharmacodynamic evaluation.

Authors:  R Zain-Hamid; Z Ismail; S Mahendra Raj; I L Shuaib; S S J Mohsin
Journal:  Malays J Med Sci       Date:  2003-01

4.  A randomised controlled trial of propranolol for the prevention of initial bleeding in cirrhotic patients with portal hypertension. Preliminary results. The Italian Multicenter Project for Propranolol in the Prevention of Bleeding.

Authors:  L Pagliaro; L Pasta; G D'Amico
Journal:  Drugs       Date:  1989       Impact factor: 9.546

5.  Hemodynamic effects of one week of carvedilol administration on cirrhotic rats.

Authors:  Han-Chieh Lin; Yi-Tsau Huang; Hung-Chi Wei; Ying-Ying Yang; Tzung-Yan Lee; Ying-Wen Wang; Ming-Chih Hou; Shou-Dong Lee
Journal:  J Gastroenterol       Date:  2006-04       Impact factor: 6.772

Review 6.  Carvedilol vs endoscopic band ligation for the prevention of variceal bleeding: a meta-analysis.

Authors:  Shan Tian; Ruixue Li; Yingyun Guo; Xuemei Jia; Weiguo Dong
Journal:  Ther Clin Risk Manag       Date:  2019-01-29       Impact factor: 2.423

7.  Adherence to Non-Selective Beta Blockers for Prevention of Variceal Bleeding in Cirrhotic Patients.

Authors:  Yang An; Xiangbo Xu; Tianshu Ren; Zhenhua Tong; Fernando Gomes Romeiro; Andrea Mancuso; Xiaozhong Guo; Xingshun Qi
Journal:  Int J Gen Med       Date:  2021-10-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.